Mavacamten is a selective, reversible myosin-inhibitor licensed in the United Kingdom as an oral therapy to treat symptomatic obstructive Hypertrophic Cardiomyopathy (oHCM) [1, 2]. This evidence concerns the gene MYH14 and hypertrophic cardiomyopathy.